A federal magistrate judge’s July 10, 2026 scheduling order setting the first LINX reflux device lawsuit for trial on June 22, 2027 has sharpened attention on litigation that has quietly grown in Minnesota and Massachusetts federal courts. The order — issued by U.S. Magistrate Judge Elizabeth Cowan Wright in Colunga v. Torax Medical/Ethicon (D. Minnesota) — arrives just months after Johnson & Johnson completed its full withdrawal of the LINX Reflux Management System from all markets outside the United States, a process that concluded in March 2026 following J&J’s September 2025 announcement. For the thousands of patients who received LINX implants and later required device removal or revision surgery, the convergence of these events — combined with a $103.8 million settlement and a $25 million verdict already secured by plaintiffs — makes 2026 the most consequential moment yet in LINX reflux device lawsuit history.
What Is the LINX Device and Why Are Patients Suing?
The LINX Reflux Management System is a small ring of titanium-encased magnetic beads surgically implanted around the lower esophageal sphincter (LES) to treat chronic gastroesophageal reflux disease (GERD). The device was designed by Torax Medical and received FDA premarket approval (PMA) in 2012 under application number P100049. Johnson & Johnson’s Ethicon subsidiary acquired Torax in 2017, inheriting both the product and its growing safety record. According to peer-reviewed literature and device tracking data, more than 40,000 LINX devices have been implanted globally since FDA approval in 2012.
The central allegation in every active LINX reflux device lawsuit traces back to a manufacturing defect: titanium beads can separate from their wire links, creating what the FDA described as a “discontinuous or open” device. Once the ring loses structural integrity, it can migrate within the body, puncture surrounding organs, erode into the esophagus, or cause dense scar tissue adhesions to the liver, colon, or lungs. The American Gastroenterological Association has specifically flagged LINX erosion as “a significant risk,” adding clinical weight to patient claims. Plaintiffs who underwent painful revision surgery or full explantation — sometimes years after implantation — now argue that Torax and Ethicon knew about the defect and failed to address it adequately before placing devices in tens of thousands of patients.
The 2018 Recall: Manufacturing Defect at the Core of Every Viable Claim
In May 2018, Torax Medical issued a Class II recall covering 9,131 LINX devices after confirming that a manufacturing defect allowed the titanium beads to separate from their wire links. The recall was classified Class II — meaning the FDA determined the defect could cause temporary or medically reversible adverse health consequences, though not ruling out more serious outcomes. By the time the recall was announced, at least 526 adverse events had already been reported to the FDA’s Manufacturer and User Facility Device Experience (MAUDE) database, many specifically involving bead separation and device migration — the exact failure mode the recall addressed.
The recall is more than a safety milestone; it is the legal linchpin of every surviving LINX reflux device lawsuit. Because LINX is a PMA-approved device, federal preemption under Riegel v. Medtronic (2008) bars plaintiffs from pursuing state-law claims that impose requirements different from or in addition to FDA requirements. That means design defect and failure-to-warn theories are largely foreclosed. What survives preemption is the “parallel claim” doctrine: plaintiffs can sue under state law when they allege the manufacturer violated the FDA’s own requirements — and the 2018 recall provides exactly that hook. Plaintiffs argue that Torax and Ethicon deviated from FDA-approved manufacturing specifications, causing the bead separation the recall confirmed. This narrow but powerful theory is why the recall date and its documentation remain the foundation of every complaint filed through 2026.
Key LINX Litigation Statistics at a Glance
As of September 2026, the LINX litigation landscape reflects both the scale of harm alleged and the financial stakes now in play for Johnson & Johnson’s Ethicon subsidiary. The following figures capture where the litigation stands heading into the first scheduled trials:
- $103.8 million — Total settlement value reached in LINX product liability lawsuits as of September 2026
- $25 million — Jury verdict secured against Ethicon in LINX litigation as of September 2026
- 40,000+ — LINX devices implanted globally since FDA approval in 2012
- 9,131 — Devices covered by the May 2018 Class II manufacturing defect recall
- 526+ — Adverse events reported to the FDA MAUDE database at the time of the recall
- March 2026 — Date J&J completed its full withdrawal of LINX from all non-U.S. markets
- June 22, 2027 — Date of the first scheduled federal jury trial (Colunga v. Torax Medical/Ethicon, D. Minnesota)
- May 12, 2028 — Scheduled trial date for Wingett v. Ethicon (D. Minnesota)
- September 2028 — Date of the second scheduled federal jury trial per the court’s scheduling order
These numbers underscore a litigation environment that has shifted meaningfully in plaintiffs’ favor heading into 2026’s final months. With over $103 million already resolved and a $25 million verdict on record, J&J faces intensifying pressure as bellwether trials approach.
J&J’s Global Market Withdrawal: What It Means for Litigation
Johnson & Johnson’s decision to pull the LINX device from every market outside the United States was completed in March 2026, following the company’s September 2025 public announcement of its intent to exit those markets. The withdrawal was global in scope: LINX is no longer sold, distributed, or commercially supported in Europe, Asia, Australia, or any other non-U.S. jurisdiction where it had previously been available. In the United States, the device technically remains on the market with FDA approval, but the practical significance of that distinction has narrowed considerably.
For active plaintiffs and their attorneys, J&J’s market exit carries several layers of meaning. First, it removes any commercial incentive the company might have had to defend the device aggressively at trial — a corporation no longer profiting from a product has less business reason to rehabilitate its reputation at the cost of prolonged, high-profile litigation. Second, the withdrawal can be presented to juries as circumstantial evidence of corporate acknowledgment that the device presented unacceptable risks, even if J&J characterizes the decision in purely business terms. Defense attorneys will fight hard to exclude or contextualize that evidence, but the withdrawal is now a fact in the public record that plaintiff counsel will use in every courtroom from 2026 forward.
Third, and perhaps most practically, the global exit has consolidated J&J’s legal exposure. Foreign plaintiffs who might have pursued claims in their home countries under more permissive liability frameworks now face jurisdictional hurdles that could push their claims into U.S. courts or leave them without viable options entirely. The net effect is that U.S. federal courts — primarily in Minnesota and Massachusetts — remain the principal arena for LINX litigation, and the cases pending there carry amplified significance for the full universe of injured patients worldwide.
Trial Calendar: Three Cases Now Scheduled in Federal Court
The LINX litigation entered a new phase in 2026 with the emergence of a concrete trial calendar. Three cases are now scheduled for federal jury trials, giving plaintiffs’ attorneys their first real opportunity to test the manufacturing-defect theory before a jury and establish damages benchmarks that will influence settlement negotiations across the broader docket.
The lead case, Colunga v. Torax Medical/Ethicon in the District of Minnesota, was set for trial beginning June 22, 2027 by U.S. Magistrate Judge Elizabeth Cowan Wright’s July 10, 2026 scheduling order. The Colunga case is expected to serve as the primary bellwether — its outcome will send the clearest signal about how Minnesota juries respond to the parallel-claim manufacturing defect theory and what damages are appropriate for patients who suffered device migration, erosion, or required complex explantation surgery.
A second case, Wingett v. Ethicon — the Janet Wingett case — is scheduled for jury trial beginning May 12, 2028, also in the District of Minnesota. The Wingett trial will provide plaintiffs and defendants alike with a second data point on jury reception of the core liability theory, and its proximity to the Colunga verdict (assuming that trial proceeds on schedule) means the two results together could rapidly accelerate or complicate global settlement discussions.
A third trial has been scheduled for September 2028 pursuant to a separate federal judge’s scheduling order, adding further pressure on J&J to resolve the broader docket before multiple adverse verdicts can accumulate. With a $25 million verdict already on record and $103.8 million in settlements reached as of September 2026, the trajectory of the litigation is clear: defendants face mounting financial exposure with each trial that proceeds to judgment.
Who Qualifies to File a LINX Reflux Device Lawsuit?
Not every patient who received a LINX device has a viable claim, and understanding the eligibility criteria is essential before consulting an attorney. The litigation’s narrow legal theory — manufacturing defect under the parallel-claim doctrine — means that qualifying plaintiffs must generally meet several specific criteria.
Device implantation within the recall window. The May 2018 Class II recall covered 9,131 specific devices identified by lot number. Patients who received a recalled device, or who can establish their device was manufactured under the conditions that gave rise to the defect, are in the strongest position. Attorneys will typically request surgical records and device lot numbers as the first step in evaluating any potential claim.
Documented physical injury requiring intervention. Because LINX litigation is grounded in manufacturing defect rather than the device’s general design, plaintiffs need to demonstrate actual physical harm — not merely dissatisfaction with reflux control or minor side effects. The injuries most commonly supporting viable claims include: bead separation or device fracture confirmed by imaging; device migration to adjacent structures; esophageal erosion or perforation caused by the device; dense adhesions requiring complex surgical dissection; and explantation surgery, whether laparoscopic or open.
Causation linkage between the defect and the injury. Medical records, operative reports, and expert testimony must connect the specific manufacturing defect — bead separation from wire links — to the plaintiff’s injuries. Patients whose complications arose from causes unrelated to the manufacturing defect (for example, surgical technique issues unrelated to the device’s structural integrity) face a more difficult causation argument.
Statute of limitations compliance. Product liability statutes of limitations vary by state but typically run two to three years from the date the plaintiff knew or should have known of the injury and its connection to the device. Given that many LINX injuries manifested years after implantation and that patients were not always informed of the recall, discovery-rule tolling arguments have preserved claims that might otherwise appear time-barred. However, the window is narrowing in 2026 for patients implanted in the 2012–2019 period who have not yet filed.
Patients who believe they may qualify should gather and preserve: surgical implantation records including device lot number; imaging studies (X-ray, CT, MRI) showing device position or failure; records of any follow-up procedures, explantation, or revision surgery; and documentation of ongoing symptoms, lost wages, and medical expenses. An attorney experienced in medical device litigation can evaluate these materials and advise on viability without charge under the contingency-fee arrangements standard in this area of practice.
Frequently Asked Questions About the LINX Reflux Device Lawsuit
What injuries are most commonly linked to the LINX device in current lawsuits?
The injuries driving active LINX litigation in 2026 center on the physical consequences of bead separation and device structural failure. The most frequently alleged injuries include esophageal erosion — where the device or separated components wear through the esophageal wall — and device migration, in which loose beads or the destabilized ring move to adjacent anatomical locations including the stomach, liver, or lung. Dense fibrous adhesions that form between the device and surrounding organs create their own injury category, as their surgical release carries significant risk of damage to the esophagus, stomach, colon, or adjacent vasculature. Many plaintiffs describe the explantation surgery itself as among the most traumatic medical experiences of their lives, involving extensive dissection, prolonged hospitalization, and lengthy recovery. Chronic dysphagia (difficulty swallowing) that worsens rather than improves over time, recurrent GERD symptoms after implantation, and esophageal perforation have also been documented in MAUDE database reports and feature in filed complaints.
Why can’t LINX plaintiffs sue for design defects or failure to warn?
The answer lies in the federal preemption doctrine established by the Supreme Court in Riegel v. Medtronic, Inc., 552 U.S. 312 (2008). Because the LINX device received FDA premarket approval — the most rigorous regulatory pathway for medical devices — federal law preempts any state-law claim that would impose requirements on the device’s design, labeling, or warnings that are “different from, or in addition to” the FDA’s own requirements. Design defect claims argue the device should have been built differently; failure-to-warn claims argue the labeling should have said more. Both theories run directly into preemption because they ask a jury to second-guess the design and labeling choices the FDA specifically approved. The only viable path around preemption is the parallel-claim exception: plaintiffs can proceed under state law when they allege the manufacturer violated the FDA’s own manufacturing specifications — not that the FDA-approved design was wrong, but that the manufacturer failed to build the device the way the FDA approved. The 2018 manufacturing recall, which confirmed that bead separation resulted from a deviation from approved manufacturing processes, is what gives LINX plaintiffs their parallel-claim foothold.
Is there an MDL for LINX lawsuits, and what courts are handling these cases?
As of 2026, there is no consolidated Multidistrict Litigation (MDL) for LINX cases. The litigation remains distributed across individual federal court dockets, with the District of Minnesota and the District of Massachusetts serving as the primary venues. The District of Minnesota is currently the more active forum, hosting the Colunga bellwether trial scheduled for June 2027 and the Wingett trial scheduled for May 2028. The absence of an MDL means there is no single transferee judge coordinating discovery across all cases, which increases the burden on individual plaintiff firms but also means that favorable rulings in Minnesota or Massachusetts can build precedent without the complications of centralized MDL management. Attorneys monitoring the docket have not ruled out a future MDL petition if case filings accelerate following the first bellwether verdicts, but no such petition has been filed as of the publication date of this article.
What does J&J’s withdrawal of LINX from international markets mean for my case?
If you are a U.S. plaintiff, J&J’s March 2026 completion of its global market exit has several practical implications. It signals that the company has concluded the device’s commercial future outside the United States is not worth defending, which plaintiff attorneys will argue reflects an implicit corporate acknowledgment of the device’s risk profile. At trial, the admissibility of evidence about the withdrawal will be contested — defendants will argue it was a business decision unrelated to product safety — but the fact of the withdrawal is now part of the litigation landscape that both sides must navigate. For patients outside the United States who received LINX implants and suffered injuries, the picture is more complicated: with no ongoing commercial presence in their countries, J&J has less exposure to local regulatory action, and those patients may face significant hurdles pursuing claims in their home jurisdictions. U.S.-based attorneys with international device litigation experience should be consulted about whether U.S. courts could exercise jurisdiction over foreign plaintiffs’ claims.
What is the statute of limitations for filing a LINX device lawsuit in 2026?
The statute of limitations for product liability claims varies by state, but most states set the window at two to three years from the date the plaintiff knew or reasonably should have known of the injury and its likely cause. For LINX patients, that clock typically begins running not at implantation, but when symptoms serious enough to prompt investigation emerged, when imaging confirmed device failure, or when a physician informed the patient that the LINX device was responsible for their complications. Because many patients suffered injuries years after implantation — and because the 2018 recall was not widely publicized to implant recipients — courts have generally been receptive to discovery-rule tolling arguments that extend the filing window. However, 2026 represents a critical inflection point: patients who were implanted between 2012 and 2020 and who have experienced complications need to consult with an attorney immediately to assess whether their claims remain timely. Waiting for bellwether trial results before filing is a strategy that carries real risk of time-bar, and no potential plaintiff should assume that ongoing litigation automatically preserves their individual claim.
Victoria Chambers is a mass tort and class action research analyst with extensive knowledge of multi-district litigation (MDL), defective product cases, dangerous drug lawsuits, and toxic exposure claims across the United States. Victoria is not an attorney and the information provided is for educational purposes only.